Give us a call

Thank you for your interest in CSL. We care about your questions and concerns. You can find the best way to contact us from the list below.

CSL Parkville office

General Enquiries

CSL Limited Head Office

Phone: +61 3 9389 1911
Fax: +61 3 9389 1434

Submit general enquiries

Media Enquiries

Christina Hickie

CSL Limited
Senior Manager, Communications
Mobile: +61 429 609 762
Phone: +61 3 9389 3425


Chris Florentz

CSL Behring
Manager, External Communications
Phone: +1 610 878 4316

Country Contacts

CSL Behring

Investors

Bernard Ronchi

CSL Limited Investor Relations
Phone: +61 3 9389 3470

Computershare

The CSL share registry is managed and maintained by Computershare.
Phone: 1800 646 882
Outside Australia: +61 3 9415 4178
Fax: +61 3 9473 2500
Website: www.investorcentre.com

Medical Information

Adverse Event Within Australia

Pharmaceuticals and vaccines


Phone: 1800 008 275

Customer Service

Within Australia

Plasma-Derived Therapies

Phone: 1800 063 892

Pharmaceuticals and Vaccines

Phone: 1800 008 275

Outside Australia

Seqirus

Phone: 1800 008 275
Email: service.uk@seqirus.com

Seqirus

Seqirus is the world’s No. 2 influenza vaccine provider in sales with operations in more than 20 countries in the US$4 billion global industry. Seqirus provides a differentiated product portfolio, possesses strong pandemic and prepandemic franchises and manages one of the world’s largest influenza vaccine manufacturing networks with operations on three continents: North America, Europe and Australia.

CSL Behring

We are committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in our support of therapies for people with deficient or malfunctioning blood proteins that cause diseases like bleeding disorders, primary immune deficiencies and Alpha-1 proteinase inhibitor deficiencies.